"Biocon Executive Chairperson Kiran Mazumdar-Shaw stated the company aims to be the world's number one insulin supplier in five years. The company is capitalizing on Big Pharma's shift toward GLP-1 weight-loss drugs. Biocon is currently the third-largest insulin supplier globally."